UltraGreen.ai, a leader in fluorescence-guided surgery and digital health solutions, has achieved significant regulatory milestones with approvals for its Verdye (indocyanine green for injection) in the Philippines and IC-Flow Imaging System V2 in Malaysia. These approvals mark a crucial step in the company’s strategic expansion across Southeast Asia, a region experiencing a surge in healthcare demand.
The approvals enable UltraGreen and its local partners to support education, training, and the broader clinical adoption of indocyanine green-based techniques among surgeons in both countries. This development is particularly timely as surgical demand rises in oncology, colorectal, and reconstructive care across the region.
Fluorescence-guided surgery using indocyanine green has become an essential tool in various surgical procedures. The IC-Flow Imaging System V2’s approval in Malaysia facilitates the use of fluorescence imaging technology in clinical settings, whilst Verdye’s approval provides Filipino clinicians access to a globally recognised, high-quality product.
Declan Cassells, Chief Operating Officer of UltraGreen, stated, “These approvals represent far more than regulatory milestones – they pave the way for delivering proven surgical technologies to healthcare systems across Southeast Asia.”
UltraGreen’s commitment to advancing precision surgery through high-quality pharmaceutical, imaging, and data-driven solutions is further solidified by these approvals, strengthening its presence in Southeast Asia.
